Connect your AI

Novavax NVAX Proceeds from sale of assets

Proceeds from sale of assets at other companies

SEN

Seneca FoodsSENEA

$635K-86.1%

WingstopWING

$0-100%

TDA

USA TODAY Co., Inc.TDAY

$9.26M-80.9%

Symbotic Inc.SYM

$0—

Amneal Pharmaceuticals, Inc.AMRX

$523.5K—

MTD

Matador ResourcesMTDR

$5.61M+81.3%

Other financials

Income statement

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

Market cap$1.46B+35.6%

Enterprise value$1.53B+76.9%

P/S2.5×+1.6×

Profitability

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfOtherProductiveAssets.

The official record: Novavax’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's proceeds from sale of assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Novavax's proceeds from sale of assets?: Novavax (NVAX) reported proceeds from sale of assets of $0 in Q4 2025.
How has Novavax's proceeds from sale of assets changed year-over-year?: Novavax's proceeds from sale of assets decreased by 100.0% year-over-year, from $48.16M to $0.